AR066078A1 - Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos. - Google Patents
Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos.Info
- Publication number
- AR066078A1 AR066078A1 ARP080101564A ARP080101564A AR066078A1 AR 066078 A1 AR066078 A1 AR 066078A1 AR P080101564 A ARP080101564 A AR P080101564A AR P080101564 A ARP080101564 A AR P080101564A AR 066078 A1 AR066078 A1 AR 066078A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- alkoxy
- aryl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NYOWYNSNCXRVNQ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indazole Chemical compound C1=CCC2CNNC2=C1 NYOWYNSNCXRVNQ-UHFFFAOYSA-N 0.000 title 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical class C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- -1 C2-14 alkynyl Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- YKPQUSLRUFLVDA-UHFFFAOYSA-N $l^{2}-azanylmethane Chemical compound [NH]C YKPQUSLRUFLVDA-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procesos de obtencion y usos de los mismos para tratar y/o prevenir enfermedades y/o trastornos aliviados por la inhibicion de la Proteína de Choque Térmico 90. La presente además proporciona composiciones farmacéuticas que comprenden dichoscompuestos. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque: R1 y R2 son independientemente -H o alquilo C1-8, R3 está ausente o es -H, -F, -OCH3; R4 y R5 son independientemente-H, -F, -OCH3; R6 es alquenilo C2-14, alquilo C1-14, alquinilo C2-14, arilo, arilo alquilo C1-8, cicloalquenilo C3-8, cicloalquenilo C3-8-alquilo C1-8, cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-8, heteroarilo, heteroarilo alquilo C1-8,heteroarilo alquiltio C1-8-alquilo C1-8, heteroariltio alquilo C1-8, heterociclilo, heterociclo alquilo C1-8, o hidroxi alquilo C1-8, en donde el grupo R6 se sustituye opcionalmente con 1, 2, 3, 4, o 5 grupos los cuales son alquenilo C2-8, alcoxi C1-8, alcoxi C1-8-alquilo C1--8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C1-8, alquilcarboniloxi C1-8, alquilsulfinilo C1-8, alquilsulfonilo C1-8, alquiltio C1-8, alquinilo C2-8, carboxi, carboxi alquilo C1-8, ciano, ciano alquilo C1-8,cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-8, formilo, halo alcoxi C1-8, halo alquilo C1-8, halogeno, hidroxi, hidroxi alcoxi C1-8, hidroxi alcoxi C1-8-alcoxi C1-8, hidroxi alquilo C1-8, mercapto, nitro, -NR11R12, (NR11R12) alquilo C1-8,carbonilo (NR11R12), oxo, HOCH2CH(NH2)C(O)O-, NH2(CH2)mC(O)O-, CH3NH(CH2)mC(O)O-, (CH3)2N(CH2)mC(O)O-, NH2(CH2)tC(O)NH(CH2)mC(O)O-, R12CH(NH2)C(O)O-, NH2(CH2)mC(R12)2(CH2)mC(O)O-, NH2CH2CH2C(O)O-, R11ON=CH(CH2)nO-, o HONHC(O)(CH2)nO-; o R5 y R6tomados junto con el átomo de nitrogeno al cual están unidos forman un heteroarilo, en donde el heteroarilo es imidazolilo, oxazolilo, pirazolilo, piridazinilo, piridinilo, pirazinilo, pirrolilo, o tiazolilo, en donde el heteroarilo se sustituyeopcionalmente con alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C1-8, alquilcarboniloxi C1-8, arilo, arilo alquilo C1-8, ciano, ciano alquilo C1-8, cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-8, halo alcoxi C1-8, halo alquiloC1-8, halogeno, heteroarilo, heteroarilo alquilo C1-8, heterociclilo, heterociclo alquilo C1-8, hidroxi, hidroxi alquilo C1-8, mercapto, nitro, -NR11R12, (NR11R12) alquilo C1-8, o carbonilo (NR11R12); R7 es -H o alquilo C1-8; R8 es alquenilo C2-8,alquilo C1-8, alquinilo C2-8, cicloalquenilo C3-8, cicloalquenilo C3-8 alquilo C1-8, cicloalquilo C3-8, cicloalquilo C3-8 alquilo C1-8, arilo, arilo alquilo C1-8, halo alquilo C1-8, heteroarilo, heteroarilo alquilo C1-8, heterociclilo, heterocicloalquilo C1-8, o hidroxi alquilo C1-8; R9 y R10 son independientemente -H o alquilo C1-8; o R9 y R10 tomados junto con el átomo de carbono al cual están unidos forman cicloalquilo C3-8; R11 y R12 son independientemente -H, alquenilo C2-8, alquilo C1-8, alquilcarbonilo C1-8, alquinilo C2-8, arilo, arilo alquilo C1-8, cicloalquilo C3-8, cicloalquilo C3-8 alquilo C1-8, formilo, heteroarilo, heteroarilo alquilo C1-8, heterociclilo, o heterociclo alquilo C1-8; o dos grupos R12 junto con el carbonoal cual están unidos forman un grupo cicloalquilo C3-8; n es 1, 2, 3, 4, 5, o 6; cada m es independientemente 1, 2, 3, o 4; cada t es independientemente 1, 2, 3, o 4; X es H o CR13, Y es C o N; y R13 es -H o alquilo C1-8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91208307P | 2007-04-16 | 2007-04-16 | |
| US1746907P | 2007-12-28 | 2007-12-28 | |
| US1973208P | 2008-01-08 | 2008-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066078A1 true AR066078A1 (es) | 2009-07-22 |
Family
ID=39769290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101564A AR066078A1 (es) | 2007-04-16 | 2008-04-16 | Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080269193A1 (es) |
| EP (1) | EP2146967A2 (es) |
| JP (1) | JP2010524950A (es) |
| AR (1) | AR066078A1 (es) |
| CA (1) | CA2684240A1 (es) |
| CL (1) | CL2008001069A1 (es) |
| TW (1) | TW200906394A (es) |
| UY (1) | UY31027A1 (es) |
| WO (1) | WO2008130879A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588960A (en) * | 2005-02-25 | 2012-06-29 | Serenex Inc | Tetrahydroindolone and tetrahydroindazolone derivatives |
| WO2008024977A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| CN101955461B (zh) * | 2010-10-08 | 2012-11-21 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
| WO2012100135A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Picolinamide inhibitors of kinases |
| AR088082A1 (es) * | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| US9738643B2 (en) | 2012-08-06 | 2017-08-22 | Duke University | Substituted indazoles for targeting Hsp90 |
| MX355943B (es) | 2013-06-26 | 2018-05-07 | Abbvie Inc | Carboxamidas primarias como inhibidores de btk. |
| CN103467356B (zh) * | 2013-08-12 | 2015-04-01 | 绍兴文理学院 | 一种四氢吲哚化合物及其制备方法与应用 |
| WO2016040809A1 (en) * | 2014-09-11 | 2016-03-17 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
| US20160143884A1 (en) | 2014-11-26 | 2016-05-26 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
| WO2017059434A1 (en) | 2015-10-02 | 2017-04-06 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of cancer |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| JOP20190080A1 (ar) * | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| US10975030B2 (en) | 2016-10-31 | 2021-04-13 | University Of Kansas | Grp94 selective inhibitors and uses thereof |
| CN109796409A (zh) * | 2019-01-31 | 2019-05-24 | 广州暨南生物医药研究开发基地有限公司 | 一种合成四氢吲唑化合物的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208630B2 (en) * | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| NZ588960A (en) * | 2005-02-25 | 2012-06-29 | Serenex Inc | Tetrahydroindolone and tetrahydroindazolone derivatives |
| WO2006133634A1 (en) * | 2005-06-14 | 2006-12-21 | Beijing Gylongly Biodemtech Co., Ltd | Tetrahydroindole derivatives and tetrahydroindazole derivatives, and use thereof |
| EP1924557A2 (en) * | 2005-09-16 | 2008-05-28 | Serenex, Inc. | Carbazole derivatives |
| JP2009532329A (ja) * | 2006-02-27 | 2009-09-10 | セレネックス， インコーポレイテッド | シクロヘキシルアミノ、ベンゼン、ピリジン及びピリダジン誘導体 |
| US20080070933A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Purine, Pyrimidine, and Azaindole Derivatives |
| WO2008024980A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| WO2008024963A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| WO2008024977A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
| US20080070918A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives |
| US20080119457A1 (en) * | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| WO2008024970A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| US20080070930A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Pyrimidine and Pyrazine Derivatives |
-
2008
- 2008-04-14 US US12/102,128 patent/US20080269193A1/en not_active Abandoned
- 2008-04-14 WO PCT/US2008/060173 patent/WO2008130879A2/en not_active Ceased
- 2008-04-14 CA CA002684240A patent/CA2684240A1/en not_active Abandoned
- 2008-04-14 JP JP2010504173A patent/JP2010524950A/ja not_active Withdrawn
- 2008-04-14 EP EP08799842A patent/EP2146967A2/en not_active Withdrawn
- 2008-04-15 CL CL200801069A patent/CL2008001069A1/es unknown
- 2008-04-16 TW TW097113864A patent/TW200906394A/zh unknown
- 2008-04-16 AR ARP080101564A patent/AR066078A1/es unknown
- 2008-04-16 UY UY31027A patent/UY31027A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001069A1 (es) | 2008-08-08 |
| WO2008130879A3 (en) | 2008-12-18 |
| WO2008130879A2 (en) | 2008-10-30 |
| JP2010524950A (ja) | 2010-07-22 |
| US20080269193A1 (en) | 2008-10-30 |
| TW200906394A (en) | 2009-02-16 |
| EP2146967A2 (en) | 2010-01-27 |
| UY31027A1 (es) | 2008-11-28 |
| CA2684240A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066078A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos. | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| ME02453B (me) | Inhibitori protein kinaze | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR082763A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
| AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
| AR081587A1 (es) | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. | |
| NZ704738A (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| SI2797921T1 (en) | Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors | |
| AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
| AR062526A1 (es) | DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER. | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| HRP20190805T1 (hr) | Spojevi triazolopirimidina i njihova uporaba | |
| AR070079A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| JP2016506960A5 (es) | ||
| RU2017123114A (ru) | 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR075253A1 (es) | Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |